StreetAlpha.app
Home › Stocks › CLYM

Climb Bio, Inc. (CLYM)

Healthcare
$9.78
▼ −1.61%
LAST CLOSE · NOV 17

Climb Bio develops antibody medicines for immune system diseases, including rare kidney and blood disorders. It last closed at $9.78 on Nov 17, down 1.61% on the day. The average 12-month price target from 7 analysts is $28.14 (+187.8% from the last close), with a high of $32.00 and a low of $25.00. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (7 buy, 0 hold, 0 sell).

AI Auto Pilots
Is CLYM in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$59.3M
EPS (diluted)
−$0.81
Free cash flow
−$53.6M
Valuation
Market cap
$574.5M
58.7M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$39.7M
At Sep 30
Shareholder equity
$228.1M
Shares outstanding
58.7M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$47.5M−$47.5MFY2021FY2022: −$45.2M−$45.2MFY2022FY2023: −$35.1M−$35.1MFY2023FY2024: −$73.9M−$73.9MFY2024FY2025: −$59.9M−$59.9MFY2025

From CLYM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 7 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
7firms
7 Buy0 Hold0 Sell
Each firm's latest rating on CLYM in the past 90 days
Average 12-month target
$28.14
▲ 187.8% upside

Based on 7 analysts who set a price target on CLYM in the past 90 days. The average target is $28.14, with a high of $32.00 and a low of $25.00, compared with the last close of $9.78.

Low $25.00Avg $28.14High $32.00
Blue marker: last close $9.78
Highest target$32.00
Average target$28.14
Lowest target$25.00
Latest rating changes
WedbushTarget raised
Nov 6Buy$20 → $27
Deutsche BankInitiated
Oct 20Buy$28
OppenheimerMaintained
Sep 8Buy$25
HC Wainwright & Co.Target raised
Sep 8Buy$24 → $30
B. Riley SecuritiesReiterated
Sep 4Buy$30
DateFirmActionRatingPrice target
Nov 6WedbushTarget raisedBuy$20 → $27
Oct 20Deutsche BankInitiatedBuy$28
Sep 8OppenheimerMaintainedBuy$25
Sep 8HC Wainwright & Co.Target raisedBuy$24 → $30
Sep 4B. Riley SecuritiesReiteratedBuy$30
Loading…

Technical Analysis

CLYM · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend

The stock is 5% below its 20 day and 16% below its 50 day average. It is 10% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 44). The nearest support is the swing low (Oct 19) at $9.61, and the nearest resistance the Pivot at $9.86.

Short trendBearish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityNormal, 9.6%/day
Key levels
$18.3352 week high+87.4%
$12.72100 day average+30.1%
$11.3450 day average+16.0%
$10.72200 day average+9.6%
$10.55Swing high (Oct 29)+7.9%
$10.34Pivot R1+5.7%
$10.2320 day average+4.6%
$9.86Pivot+0.8%
$9.78Last close
$9.61Swing low (Oct 19)−1.7%
$9.29Pivot S1−5.0%
$1.6452 week low−83.2%
Indicators
RSI (14)44.05Middle of its rangeNeutral
MACD-0.19Above its signal lineBullish
Stochastic39.0Middle of its rangeNeutral
ADX (14)27.0Trending down
Williams %R-67.3Oversold below −80, overbought above −20Neutral
CCI (20)-43.4Oversold below −100, overbought above 100Neutral
Rate of change+0.3%Change over 10 sessionsBullish
ATR (14)$0.93Typical daily range, 9.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CLYM

What happened before

See how CLYM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in CLYM in the last 90 days.

Loading…

See today’s whale options flow across the market →

CLYM Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲89 buying vs 35 selling
  • ▲Held by funds +15.0 pts
  • ▲Funds holding +19
  • ▼Superinvestors: 0 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding128109+17.4%
In funds' top 10110.0%
Held by funds110.9%95.9%+15.0 pts
New / increased31 / 5852 / 32+6.0%
Reduced / sold out22 / 1318 / 22−12.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CLYM institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CLYM is in one of them and how their past CLYM trades turned out.

CLYM in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CLYM in an article yet. Here's the latest on the wider market.

About Climb Bio

Climb Bio is a biotechnology company based in Wellesley Hills, Massachusetts. It is developing antibody medicines for diseases in which the immune system attacks the body. Its lead candidate, budoprutug, is designed to deplete a type of B cell and is being tested in patients with membranous nephropathy, a rare kidney disease, as well as immune thrombocytopenia and lupus. A second candidate, CLYM116, targets a protein linked to IgA nephropathy, a kidney condition. Its candidates are still in clinical trials and are not yet sold.

Headquarters
Wellesley Hills, MA